Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19188091 | 0.85 | NPC1 (0.56) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL29522878 | 0.83 | DYRK1A (0.53) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2739230 | 0.83 | DYRK1A (0.53) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL16132873 | 0.78 | GRM5 (0.51) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL20698180 | 0.78 | FGFR1 (0.54) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL4814996 | 0.78 | GRM5 (0.51) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL212673 | 0.78 | MAPT (0.61) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL21900387 | 0.78 | FGFR1 (0.54) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5343727 | 0.78 | GRM5 (0.51) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL615432 | 0.78 | GRM5 (0.51) | NPC1RAB9AGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110904473-A | 5G antenna environment-friendly copper plating process | 中山美力特环保科技有限公司 | 2020-03-24 | — | — | CN | claimed |
| US-4542394-A | MULTILAYER-DIAZONIUM LAYER AND COUPLER LAYER CONTAINING BENZIMIDAZOLE COMPOUND | RICOH COMPANY, LTD. (JP) | 1985-09-17 | — | — | US | claimed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| WO-2023249872-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-3628044-B1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192738-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-22 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| WO-2008084218-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007059257-A2 | N4-PHENYL-QUINAZ0LINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007050723-A1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| EP-0376624-B1 | 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation | YAMANOUCHI PHARMA CO LTD (JP) | 1994-09-14 | — | — | EP | disclosed |
| US-4977175-A | GASTROINTESTINAL DISORDERS, ANTIEMETICS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-12-11 | — | — | US | disclosed |
| EP-0376624-A1 | 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | NPC1 2217/4885RAB9A 198/4885GAA 3792/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | NPC1 2072/4885RAB9A 2533/4885GAA 3244/4885 |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | CHRM5, CHRM1, CHRM2 | NPC1 2791/4885RAB9A 1208/4885GAA 3814/4885 |
| US-20230192738-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OPRM1, OPRD1, OXER1 | NPC1 2178/4885RAB9A 421/4885GAA 3541/4885 |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | NPC1 559/4885RAB9A 2509/4885GAA 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.